Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States

J Am Acad Dermatol. 2015 Aug;73(2):337-8. doi: 10.1016/j.jaad.2015.04.040.

Authors

Romi Bloom¹, Kyle T Amber²

Affiliations

¹ Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Florida.
² Department of Internal Medicine, MacNeal Hospital, Berwyn, Illinois. Electronic address: KAmber@med.miami.edu.

PMID: 26183986
DOI: 10.1016/j.jaad.2015.04.040

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Murine-Derived / economics*
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Autoimmune Diseases / drug therapy*
Autoimmune Diseases / economics
Autoimmune Diseases / immunology
Databases, Factual
Drug Costs*
Female
Health Care Costs
Humans
Insurance Coverage / economics*
Insurance Coverage / statistics & numerical data
Insurance, Health / economics
Insurance, Health / statistics & numerical data
Male
Needs Assessment
Policy Making
Private Sector / economics*
Private Sector / statistics & numerical data
Rituximab
Skin Diseases, Vesiculobullous / drug therapy*
Skin Diseases, Vesiculobullous / economics
Skin Diseases, Vesiculobullous / immunology
United States

Substances

Antibodies, Monoclonal, Murine-Derived
Rituximab